Servicio de Cardiologia y Cirugia Cardíaca, Hospital Universitario Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain; Agencia de Investigación de la Sociedad Española de Cardiologia, Madrid, Spain.
Department of Cardiac Sciences, Libin Cardiovacular Institue of Alberta, University of Calgary and Population Health Research Institute-McMaster University, Hamilton, Ontario, Canada.
J Am Coll Cardiol. 2017 Oct 3;70(14):1720-1728. doi: 10.1016/j.jacc.2017.08.026.
Pacing in vasovagal syncope remains controversial.
The authors evaluated dual-chamber pacing with closed loop stimulation (DDD-CLS) in patients with cardioinhibitory vasovagal syncope.
This randomized, double-blind, controlled study included Canadian and Spanish patients age ≥40 years, with high burden syncope (≥5 episodes, ≥2 episodes in the past year), and a cardioinhibitory head-up tilt test (bradycardia <40 beats/min for 10 s or asystole >3 s). Patients were randomized to either DDD-CLS pacing for 12 months followed by sham DDI mode pacing at 30 pulses/min for 12 months (group A), or sham DDI mode for 12 months followed by DDD-CLS pacing for 12 months (group B). Patients in both arms crossed-over after 12 months of follow-up or when a maximum of 3 syncopal episodes occurred within 1 month.
A total of 46 patients completed the protocol; 22 were men (47.8%), and mean age was 56.30 ± 10.63 years. The mean number of previous syncopal episodes was 12 (range 9 to 20). The proportion of patients with ≥50% reduction in the number of syncopal episodes was 72% (95% confidence interval [CI]: 47% to 90%) with DDD-CLS compared with 28% (95% CI: 9.7% to 53.5%) with sham DDI mode (p = 0.017). A total of 4 patients (8.7%) had events during DDD-CLS and 21 (45.7%) during sham DDI (hazard ratio: 6.7; 95% CI: 2.3 to 19.8). Kaplan-Meier curve was significantly different between groups in time to first syncope: 29.2 months (95% CI: 15.3 to 29.2 months) versus 9.3 months (95% CI: 6.21 months, NA; p < 0.016); odds ratio: 0.11 (95% CI: 0.03 to 0.37; p < 0.0001).
DDD-CLS pacing significantly reduced syncope burden and time to first recurrence by 7-fold, prolonging time to first syncope recurrence in patients age ≥40 years with head-up tilt test-induced vasovagal syncope compared with sham pacing. (Closed Loop Stimulation for Neuromediated Syncope [SPAIN Study]; NCT01621464).
血管迷走性晕厥的起搏治疗仍存在争议。
作者评估了双腔起搏并闭环刺激(DDD-CLS)在心脏抑制型血管迷走性晕厥患者中的应用。
这是一项随机、双盲、对照研究,纳入了加拿大和西班牙年龄≥40 岁、晕厥负担重(≥5 次,≥1 年内≥2 次)和心脏抑制性直立倾斜试验(心率<40 次/分持续 10 秒或停搏>3 秒)的患者。患者被随机分为两组,一组在 12 个月内接受 DDD-CLS 起搏,随后在 12 个月内以模拟 DDI 模式起搏 30 次/分(A 组),另一组在 12 个月内接受模拟 DDI 模式起搏,随后在 12 个月内接受 DDD-CLS 起搏(B 组)。两组患者在 12 个月随访后或在 1 个月内发生最多 3 次晕厥事件后交叉。
共有 46 例患者完成了该方案;其中 22 例为男性(47.8%),平均年龄为 56.30±10.63 岁。平均既往晕厥发作次数为 12 次(9 至 20 次)。与模拟 DDI 模式相比,DDD-CLS 组有 72%(95%置信区间:47%至 90%)的患者晕厥发作次数减少≥50%,而模拟 DDI 模式组有 28%(95%置信区间:9.7%至 53.5%)(p=0.017)。DDD-CLS 组共有 4 例(8.7%)患者发生事件,模拟 DDI 组共有 21 例(45.7%)患者发生事件(危险比:6.7;95%置信区间:2.3 至 19.8)。Kaplan-Meier 曲线显示两组患者首次晕厥时间有显著差异:29.2 个月(95%置信区间:15.3 至 29.2 个月)与 9.3 个月(95%置信区间:6.21 个月,NA;p<0.016);优势比:0.11(95%置信区间:0.03 至 0.37;p<0.0001)。
与模拟起搏相比,DDD-CLS 起搏可显著降低晕厥负担和首次复发时间,使年龄≥40 岁、直立倾斜试验诱导的血管迷走性晕厥患者的首次晕厥复发时间延长 7 倍。(神经介导性晕厥的闭环刺激[西班牙研究];NCT01621464)。